Spread the love

–News Direct–

Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Jonathan Jackson in the Proactive studio to delve into the companys latest milestone – commencement of dosing for the first patient in the intravenous monotherapy arm of a Phase 1 clinical trial of the CD19 oncolytic virotherapy drug candidate, onCARlytics (also known as on-CAR-19, CF33-CD19 HOV4).

Dubbed OASIS, the trial focuses on adult patients grappling with advanced or metastatic solid tumours. The trial's primary objective is to assess the safety and efficacy of two administration routes: intratumoural (IT) injection and intravenous (IV) infusion, either independently or in conjunction with blinatumomab, a CD19-targeting bispecific monoclonal antibody (marketed as Blincyto by Amgen).

The combination arm of the study will merge onCARlytics with blinatumomab, presenting a promising avenue for patients who previously found limited benefit from Blincyto therapy alone.

Imugene's groundbreaking work is garnering attention, with the company recently featured on Channel 7.

Chong said: Were pleased to see onCARlytics continue to advance in the clinic after the first patient on the trial was dosed in late October, and this move into intravenous administration marks another milestone in our mission to bring innovative cancer treatments to patients in need. With the combination arm of the study still to come, we eagerly await the chance to see more on the potential onCARlytics holds."

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

[email protected]

View source version on newsdirect.com: https://newsdirect.com/news/imugene-doses-first-patient-in-intravenous-monotherapy-arm-of-phase-1-clinical-trial-566267014


comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Watch Mirror journalist was involved in the writing and production of this article.

Categories: Cloud PRWire